Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.875 4.07% 22.375 22.25 22.50 22.375 20.75 21.38 1,945,606 10:16:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.0 -18.9 -21.3 - 19

Hvivo Share Discussion Threads

Showing 4651 to 4674 of 4675 messages
Chat Pages: 187  186  185  184  183  182  181  180  179  178  177  176  Older
DateSubjectAuthorDiscuss
09/2/2023
10:28
you should have been here on the sustained fall :)

hope to see 30p sooner rather than later....

sos100
09/2/2023
10:17
Not sure I have been in a share with such a sustained rise. Had larger gains but have tended to be short term lifts after news. Something MUST be brewing. Looking forward to finding out but happy with this ride :)
inaminute
09/2/2023
10:16
This is so strong day after day. The last 2 occasions when the share price seen this kind of rise was before the government covid contracts and pre POLB announcement. The buying is relentless. I anticipate a spin off, sale of core business or both.
protrader3
09/2/2023
10:08
And yet again (imo) PIs are literally handing over their shares to institutions.Pointless fighting them. Let them take us much higher until buyout. That's what I'm waiting for anyway.
parob
09/2/2023
09:52
I think you mean,

We've all angles here.

troutisout
09/2/2023
09:48
Trout

We’re all angels here.

yump
09/2/2023
09:45
Here is the research from GlobalData which Egle mentioned in that interview I posted yesterday. Hopefully not too long before we see another deal coming out of the APAC region.Asia-Pacific attracts 50% of global clinical trials5/9/22The Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period, found research by GlobalData.The study, which was commissioned by APAC focused biotech specialist CRO, Novotech, found that all phases of clinical trials in the region registered higher growth than both the US and the EU.The region registered significantly higher growth than the US and the EU across all analysed therapeutic areas, including CNS diseases, cardiovascular diseases, gastrointestinal diseases, and infectious diseases, the latter of which witnessed the highest growth, reported the GlobalData team.  There was also 100% growth in oncology trials during the same period, according to the review.GlobalData analysis links that growth to a range of factors, including site availability, particularly for oncology trials, when compared to the US and Europe, along with lower operating costs.Overseas drug makers have never been keener to access the burgeoning APAC market, commented the researchers."The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical institutions acting as sites," said the analysts.https://www.biopharma-reporter.com/Article/2022/09/05/asia-pacific-attracts-50-of-global-clinical-trials
parob
09/2/2023
09:33
Filtering STT on here is quite amusing. He posts more than everyone who actually holds combined.

Pretty funny

lako42
09/2/2023
09:18
Pierre, your 'just a suggestion' is laughable when you are the one bickering with him, most here filtered him and others months ago, but you come and stir him up with posts like this, then you ask people to ignore him.

"Pierre Oreilly - 07 Feb 2023 - 12:30:29 - 1807 of 1934 hVIVO plc - HVO
Unlike you stt, I post my honest opinions, and have a decent slug invested.

The only place I'd point you to is the local asylum where you may have a better quality of life after suitable treatment."

Much like your winding up of yump yesterday, don't try and portray yourself as an investing angel, I remember when you slated REDT's technology on these BBs for a while then when the price dropped and you bought in, you became an REDT disciple and wouldn't let a bad word be said about it. Short memories from some, fortunately mine is very good when it comes to posters who act in this way.

troutisout
09/2/2023
09:13
All the loose stock is getting scooped up again.
parob
09/2/2023
08:34
I think we've seen that when CF has made changes to corporate structure it has been because there is a plan aligned to those changes. I would expect that plan to be in the interests of HVO shareholders - considering Mr Friel has a bit invested here.
I find the need for patience is more pleasant when waiting to see what is under the tree, behind the barn doors, or the substance of a distribution to shareholders...

Interesting season.

G.

garth
09/2/2023
08:01
It could be something innocent like a ny resolution to get his number of directorships below his number of hvo shares.
pierre oreilly
09/2/2023
07:43
I am surprised too. It could be a simple divestment to simplify his position but why would he need to do that? Spin off an obvious possibility. The recent share action does suggest related but purely speculation. We may soon find out.
inaminute
09/2/2023
07:15
Suggested that many times but always someone who replies. I often wonder if some who do are in with him or even him under another name to divert the board away from real issues. Been on my ignore a long time
inaminute
08/2/2023
22:28
Just a suggestion... Should we all ignore the attention seeking Sikh? No attention = eventually no Sikh.Unless anyone values his posts?
pierre oreilly
08/2/2023
22:22
yump...What I thought best not to say was maybe it would be an advantage to most without them as in earlier years.
staverton
08/2/2023
20:19
APAC As A Clinical Trial Powerhouse02 Nov 2022THE RISE OF APACClinical trial activity in APAC has increased considerably over the past decade. The total number of Phase I–IV trial starts in APAC increased from 4,562 trials in 2012 to 7,718 trials in 2021, with a compound annual growth rate (CAGR) of 5.4%. Much of this growth is back-ended towards recent years. In particular, almost every year since 2016 has seen double digit increases in the number of new clinical trial initiations, as shown in Exhibit 1.In contrast, the total number of trial starts in the rest of the world decreased at a CAGR of -0.4% from 8,080 trials in 2012 to 7,801 trials in 2021. These RoW trials are defined as studies that do not contain a clinical site in an APAC country, although it is worth noting that a portion of APAC trials will also have sites in other regions. As shown in Exhibit 2, the continuation of this trend will surely see APAC surpass RoW as soon as next year. For a region that has historically trailed behind the US and Europe, this recent transformation is remarkable and shows that APAC is very much on the cutting edge of clinical research.https://invivo.pharmaintelligence.informa.com/IV146738/APAC-As-A-Clinical-Trial-Powerhouse
parob
08/2/2023
20:09
APAC.

Where a significant number of people are extremely poor and so would do anything to make some money. Where gangs use their desperation to make some money.

Ethics and safety don't come into it, when it comes to making a few quid, eh.

No value for human life.

Plus there referring to traditional trials and not human challenge trials, which are higher risk.



How many of the rampers have actually backed their investment and put their name or their family forward to one of these human challenge trials???

sikhthetech
08/2/2023
20:03
If you haven't already I would highly recommend checking out the background of Egle Pavyde (Biz Dev Director, Europe & APAC) on LinkedIn. It's seriously impressive. She's the one interviewed in the link I just posted.
parob
08/2/2023
19:57
Parob

"More deals landing there will obviously push the share price higher."

Why don't the company brokers significantly increase their target price then?
What are they missing?

sikhthetech
08/2/2023
19:39
yump,

"the stocks that hit the most frequently posted about leaderboard, seem to have a boom and bust profile"

Yes, like blnx (now trmr), GBO.. the old blnx gang's shares..

What's more interesting though is that in Feb 2021, IG announced a 100% margins on 1000+ shares. Majority of these shares were smaller ones, which were frequently pumped and appeared top of the lists.
https://www.shiftingshares.com/ig-announces-100-margin-requirements-on-1000-stocks/

Look at when shares like Orph, Byot, Reat etc ALL started their long slide down. Yep, around April 2021, around 2-3 months after IG's announcement.
Coincidence!!!

PIs (traders, gamblers) who were leveraged had to increase margins or close, leading to a rush to close.

Is it a coincidence that majority of 1gw and his mates shares were on that list? Were they over leveraged and had to close their positions?

https://uk.advfn.com/cmn/fbb/thread.php3?id=49342172&from=4915&to=4915

sikhthetech
08/2/2023
19:30
More than 50% of all registered clinical trials worldwide over the last 5 years were in the APAC region, as Egle explains in this interview, so a huge market to target. They expect "strong momentum" in the region. More deals landing there will obviously push the share price higher.hTTps://youtu.be/2oZH_alNzPo
parob
08/2/2023
19:22
Must admit I'd forgotten the structure of these
inaminute
08/2/2023
18:58
Powerful momentum in play.
adorling
Chat Pages: 187  186  185  184  183  182  181  180  179  178  177  176  Older
Your Recent History
LSE
HVO
Hvivo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230209 10:31:35